The Peptide Compliance Crisis In October 2023, the FDA issued warning letters to multiple peptide providers for marketing non-approved peptides as research chemicals while clearly selling them for human use
have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis), problems with digesting food, or severe stomach problems have a history of diabetic retinopathy have type 1 diabetes are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant are breastfeeding or plan to breastfeed
Kerato sits on the 8th floor of a midtown office building, and is bustling by 10am with patients who have paid for a new eye color, and others getting some Lasik
These medications usually contain either semaglutide or tirzepatide, which are GLP-1 receptor agonists
The concern is that two of its three pharmacy partners have disciplinary histories, and its prescribing provider groups arent publicly disclosed